NovAliX Expands Cryo-electron Microscopy (Cryo-EM) Capabilities for Drug Development Offering
NovAliX, a drug discovery-focused Contract Research Organization (CRO), today announces the expansion of its cryogenic electron microscopy (cryo-EM) technology capability.
NovAliX will benefit from the implementation at its premises of Thermo Fisher Scientific’s high-resolution microscope, the Thermo Scientific Glacios Cryo-TEM, with additional micro-electron diffraction (microED) capabilities for solving protein and small molecule structures using nanoscale crystals. This enables NovAliX to integrate an upgrade of a key technology to complement its existing biophysics capabilities, which will improve the success of drug discovery programs.
For almost two decades, NovAliX has delivered structural results to its biopharmaceutical partners – staying ahead of the competition with its technology and development. In 2016, the introduction of cryo-EM in its offerings brought with it the ability to cover the entire spectrum of structural biology methodologies and to respond to the new challenges faced by the pharmaceutical industry.
“NovAliX prides itself on having pioneered this new field – with the ongoing support of Thermo Fisher. As an early adopter of cryo-EM, it has been a fascinating journey throughout,” said Denis Zeyer, CEO at NovAliX. “We have expanded our expertise considerably; deepening our understanding of how cryo-EM can contribute to drug discovery and how this fits into that workflow. For example, in April 2020, NovAliX published an open access article in Nature Communications – on a collaboration between French, German and Russian researchers, demonstrating how cryo-EM helps in understanding the resistance mechanism of Staphylococcus aureus. This fundamental research is a long way from a cure, but certainly paves the way for the design of new drugs to combat this deadly pathogen.”
The addition of this microscope coincides with the extension of the relationship between NovAliX and Thermo Fisher which started in 2016. In June 2020, Thermo Fisher entered into co-marketing agreements with NovAliX and other Contract Research Organizations to provide pharma customers with information about the different levels of cryo-EM service packages.
“Our collaboration with NovAliX enables access to cryo-EM for biopharmaceutical and drug discovery research,” said Raymond Schrijver, senior director of electron microscopy for pharma at Thermo Fisher. “Cryo-EM takes structure-based drug design into a new era; the rapid adoption of this technique will have a direct impact on understanding and treating some of the world’s most challenging diseases.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more